Interpreting Expression Data with Metabolic Flux Models: Predicting Mycobacterium tuberculosis Mycolic Acid Production
暂无分享,去创建一个
Desmond S. Lun | James E. Galagan | Jeremy Zucker | Megan Murray | Caroline Colijn | Brian Weiner | D. Branch Moody | Aaron Brandes | Maha R. Farhat | Tan-Yun Cheng | J. Galagan | D. Lun | B. Weiner | Jeremy D. Zucker | D. Moody | C. Colijn | M. Farhat | A. Brandes | T. Cheng | Megan Murray | Megan R. Murray
[1] William R Bishai,et al. Altered expression of isoniazid-regulated genes in drug-treated dormant Mycobacterium tuberculosis. , 2008, The Journal of antimicrobial chemotherapy.
[2] J N Fain,et al. Effects of menadione and vitamin K 5 on glucose metabolism, respiration, lipolysis, cyclic 3',5'-adenylic acid accumulation, and adenyl cyclase in white fat cells. , 1971, Molecular pharmacology.
[3] Gang Wu,et al. Integrative Analysis of Transcriptomic and Proteomic Data: Challenges, Solutions and Applications , 2007, Critical reviews in biotechnology.
[4] Gurdyal S Besra,et al. The methyl-branched fortifications of Mycobacterium tuberculosis. , 2002, Chemistry & biology.
[5] Roger E Bumgarner,et al. Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. , 2001, Science.
[6] B. Palsson,et al. Regulation of gene expression in flux balance models of metabolism. , 2001, Journal of theoretical biology.
[7] B. Palsson,et al. Stoichiometric flux balance models quantitatively predict growth and metabolic by-product secretion in wild-type Escherichia coli W3110 , 1994, Applied and environmental microbiology.
[8] B. Palsson,et al. Transcriptional regulation in constraints-based metabolic models of Escherichia coli Covert , 2002 .
[9] Kazuyuki Shimizu,et al. Metabolic flux analysis based on 13C-labeling experiments and integration of the information with gene and protein expression patterns. , 2004, Advances in biochemical engineering/biotechnology.
[10] Shigeo Abe DrEng. Pattern Classification , 2001, Springer London.
[11] Markus J. Herrgård,et al. Network-based prediction of human tissue-specific metabolism , 2008, Nature Biotechnology.
[12] Gang Wu,et al. Correlation between mRNA and protein abundance in Desulfovibrio vulgaris: a multiple regression to identify sources of variations. , 2006, Biochemical and biophysical research communications.
[13] David G. Stork,et al. Pattern Classification , 1973 .
[14] J D Coleman,et al. Trends in the incidence of tuberculosis in possums and livestock, associated with differing control intensities applied to possum populations , 2006, New Zealand veterinary journal.
[15] T. Myers,et al. The Transcriptional Responses of Mycobacterium tuberculosis to Inhibitors of Metabolism , 2004, Journal of Biological Chemistry.
[16] Ru Wei,et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth , 2008, Nature.
[17] Bernhard O. Palsson,et al. Context-Specific Metabolic Networks Are Consistent with Experiments , 2008, PLoS Comput. Biol..
[18] S. Klamt,et al. GSMN-TB: a web-based genome-scale network model of Mycobacterium tuberculosis metabolism , 2007, Genome Biology.
[19] Vishwanath Venketaraman,et al. Glutathione and growth inhibition of Mycobacterium tuberculosis in healthy and HIV infected subjects , 2006, AIDS research and therapy.
[20] A. Regev,et al. Distinct physiological states of Plasmodium falciparum in malaria-infected patients , 2007, Nature.
[21] Nagasuma R. Chandra,et al. Flux Balance Analysis of Mycolic Acid Pathway: Targets for Anti-Tubercular Drugs , 2005, PLoS Comput. Biol..
[22] P. Berche,et al. A single point mutation in the embB gene is responsible for resistance to ethambutol in Mycobacterium smegmatis , 1997, Antimicrobial agents and chemotherapy.
[23] J. T. Crawford,et al. ethA, inhA, and katG Loci of Ethionamide-Resistant Clinical Mycobacterium tuberculosis Isolates , 2003, Antimicrobial Agents and Chemotherapy.
[24] E. Winzeler,et al. Protein pathway and complex clustering of correlated mRNA and protein expression analyses in Saccharomyces cerevisiae , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[25] Nancy D. Connell,et al. Characterization of a Glutathione Metabolic Mutant of Mycobacterium tuberculosis and Its Resistance to Glutathione and Nitrosoglutathione , 2006, Journal of bacteriology.
[26] D. Young,et al. Molecular mechanisms of isoniazid: a drug at the front line of tuberculosis control. , 1993, Trends in microbiology.
[27] E. Muñoz-Elías,et al. Role of the methylcitrate cycle in Mycobacterium tuberculosis metabolism, intracellular growth, and virulence , 2006, Molecular microbiology.
[28] J. Menéndez,et al. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis , 2007, Nature Reviews Cancer.
[29] W. Bishai,et al. Antimycobacterial activity of cerulenin and its effects on lipid biosynthesis. , 1999, The Journal of antimicrobial chemotherapy.
[30] Paul Carroll,et al. The missing piece of the type II fatty acid synthase system from Mycobacterium tuberculosis , 2007, Proceedings of the National Academy of Sciences.
[31] Gary A. Churchill,et al. Analysis of Variance for Gene Expression Microarray Data , 2000, J. Comput. Biol..
[32] Vojo Deretic,et al. Mechanisms of action of isoniazid , 2006, Molecular microbiology.
[33] U. Alon,et al. Just-in-time transcription program in metabolic pathways , 2004, Nature Genetics.
[34] J C Sacchettini,et al. Mechanisms for isoniazid action and resistance. , 2008, Novartis Foundation symposium.
[35] J Gowrishankar,et al. Why is transcription coupled to translation in bacteria? , 2004, Molecular microbiology.
[36] G. M. Rodríguez,et al. Control of iron metabolism in Mycobacterium tuberculosis. , 2006, Trends in microbiology.
[37] G. Besra,et al. Pathway to Synthesis and Processing of Mycolic Acids in Mycobacterium tuberculosis , 2005, Clinical Microbiology Reviews.
[38] J S Blanchard,et al. Drugs that inhibit mycolic acid biosynthesis in Mycobacterium tuberculosis. , 2002, Current pharmaceutical biotechnology.
[39] Gang Wu,et al. Correlation of mRNA Expression and Protein Abundance Affected by Multiple Sequence Features Related to Translational Efficiency in Desulfovibrio vulgaris: A Quantitative Analysis , 2006, Genetics.
[40] Alfred Nordheim,et al. Comparative proteome analysis of Staphylococcus aureus biofilm and planktonic cells and correlation with transcriptome profiling , 2006, Proteomics.
[41] Bernhard O. Palsson,et al. Metabolic flux balance analysis and the in silico analysis of Escherichia coli K-12 gene deletions , 2000, BMC Bioinformatics.
[42] Chi V Dang,et al. Cancer's molecular sweet tooth and the Warburg effect. , 2006, Cancer research.
[43] Bernhard O. Palsson,et al. Investigating the metabolic capabilities of Mycobacterium tuberculosis H37Rv using the in silico strain iNJ661 and proposing alternative drug targets , 2007 .
[44] Nir Friedman,et al. Tissue classification with gene expression profiles , 2000, RECOMB '00.
[45] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[46] Xavier Charpentier,et al. MabA (FabG1), a Mycobacterium tuberculosis protein involved in the long-chain fatty acid elongation system FAS-II. , 2002, Microbiology.
[47] Galina V. Glazko,et al. A Multivariate Extension of the gene Set Enrichment Analysis , 2007, J. Bioinform. Comput. Biol..
[48] Kiyoko F. Aoki-Kinoshita,et al. From genomics to chemical genomics: new developments in KEGG , 2005, Nucleic Acids Res..
[49] E. Muñoz-Elías,et al. Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence , 2005, Nature Medicine.
[50] Clifton E. Barry,et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis , 2000, Nature.
[51] B. Palsson,et al. Saccharomyces cerevisiae phenotypes can be predicted by using constraint-based analysis of a genome-scale reconstructed metabolic network , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[52] L. Wayne,et al. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence , 1996, Infection and immunity.
[53] K. Reynolds,et al. Biosynthetic origins of the natural product, thiolactomycin: a unique and selective inhibitor of type II dissociated fatty acid synthases. , 2003, Journal of the American Chemical Society.
[54] J. Mesirov,et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.
[55] William R. Jacobs,et al. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis , 2000, Nature Medicine.
[56] R J Heath,et al. Lipid biosynthesis as a target for antibacterial agents. , 2001, Progress in lipid research.
[57] Stephen S Fong,et al. Metabolic gene–deletion strains of Escherichia coli evolve to computationally predicted growth phenotypes , 2004, Nature Genetics.
[58] B. Palsson,et al. In silico predictions of Escherichia coli metabolic capabilities are consistent with experimental data , 2001, Nature Biotechnology.
[59] Yang Liu,et al. Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages , 2003, The Journal of experimental medicine.